S5: Optimization of diploid Pichia pastoris strains for the expression of full-length monoclonal antibodies

We have developed a rapid, robust technology platform for production of full-length humanized monoclonal antibodies in Pichia pastoris.  This expression system captures all the attributes provided by this host (low cost, strain stability, etc.) while eliminating product development risk associated with untested expression systems.   The platform has been successfully run under GMP at  2000L scale with excellent reproducibility.  Our first molecule, ADL518 has already been successfully used in human clinical trials. In this presentation a novel approach for the generation of diploid Pichia pastoris strains with increased yield and purity will be discussed.